hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06355336 id: CCA/IRN-24-001 briefTitle: Real World Prostate Cancer Registry acronym: RWPCR overallStatus: RECRUITING date: 2024-03-18 date: 2034-03-18 date: 2034-03-18 date: 2024-04-09 date: 2024-04-09 name: Cincinnati Cancer Advisors class: NETWORK briefSummary: Prostate cancer is the most common cancer diagnosed in men in the USA with 268,490 cases diagnosed in 2022 constituting 27% of male cancers and 34,500 deaths (11%) occurred in same year.1 Prostate cancer is a very heterogeneous disease that has different presentations, molecular and pathological features, stages, and disease biology. The treatment options are dependent on the disease stage, its features, and the patient's condition and preferences. The disease outcome also varies significantly due to the previous heterogeneity of the features in addition to other social determinants of health.
Therefore, it is critical to obtain real-world data that reflects the actual patterns of prostate cancer presentation, work up, management, and outcome. Real World Prostate Cancer Registry (RWPCR) aims at compiling real world data from patients presented with prostate cancer in the tristate area. The data collection will be prospective and longitudinal including patients' demographics and disease characteristics, work up, management, and outcome. conditions: Prostate Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 1000 type: ESTIMATED measure: To determine practice patterns for prostate cancer in the region. measure: To determine progression free survival and overall survival of patients. measure: Prevalence of long term complications of prostate cancer treatment. sex: MALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Cincinnati Cancer Advisors status: RECRUITING city: Cincinnati state: Ohio zip: 45212 country: United States name: Dr. Jazieh role: CONTACT phone: 513-731-2273 email: a.jazieh@cincinnaticanceradvisors.org name: Amy Barber role: CONTACT phone: 5137312273 email: ctcoordinator@iresearchnetwork.com name: Abdul R Jazieh, MD, MPH role: PRINCIPAL_INVESTIGATOR lat: 39.12713 lon: -84.51435 hasResults: False
nctId: NCT06355323 id: PT22020 briefTitle: Bronchiectasis Prevalence in Patients With Primary Humoral Immunodefiency in Champagne-Ardenne Region, France acronym: PREDDICHA overallStatus: RECRUITING date: 2022-11-28 date: 2025-11-28 date: 2025-11-28 date: 2024-04-09 date: 2024-04-09 name: CHU de Reims class: OTHER briefSummary: Primary humoral immunodeficiency (PHID), such as common variable immunodefiency, are the most common symptomatic primary immunodeficiency in adults, in France. Patients are more prone to infections (particularly bacterial upper and lower respiratory tract infections), auto-immunity and atopic manifestations. Morbidity and mortality in PHID are mainly linked to the presence of bronchiectasis, which can lead to infections and to chronic respiratory failure. However, bronchiectasis in these patients can be asymptomatic for a long time. There is no known predictive factors to identify patients more susceptible to develop bronchiectasis and notably, there was no link between the number of previous infectious episodes and bronchiectasis. A marked IgM deficiency and switched memory B cell deficiency might be associated with bronchiectasis.
Thoracic CT-scan is recommended at PHID diagnosis but there is no guideline for follow-up, thus leading to bronchiectasis being under-diagnosis or leading to delayed diagnosis conditions: Primary Immunodeficiency conditions: Common Variable Immunodeficiency conditions: Igg Subclass Deficiency conditions: Selective IgM Deficiency studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SCREENING masking: NONE count: 75 type: ESTIMATED name: Blood test name: chest CT scan measure: Thoracic CTscan measure: Pulmonary Function Test measure: Pulmonary Function Test measure: Pulmonary Function Test measure: Pulmonary Function Test measure: Pulmonary Function Test measure: Pulmonary Function Test measure: 6 minutes walking test measure: 6 minutes walking test measure: 6 minutes walking test measure: 6 minutes walking test measure: Quality of life questionnaires measure: Quality of life questionnaires measure: Immunophenotyping measure: Biochemical factors : desmosine seric concentration sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Damien JOLLY status: RECRUITING city: Reims country: France name: Amélie SERVETTAZ role: CONTACT phone: 03 26 83 27 68 9 phoneExt: 0033 email: aservettaz@chu-reims.fr name: Ailsa ROBBINS role: CONTACT phone: 03 26 83 27 68 phoneExt: 0033 email: arobbins@chu-reims.fr lat: 49.25 lon: 4.03333 hasResults: False
nctId: NCT06355310 id: IRB 2023-6429 briefTitle: Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease acronym: SHIELD overallStatus: NOT_YET_RECRUITING date: 2024-05-20 date: 2028-12-31 date: 2028-12-31 date: 2024-04-09 date: 2024-04-09 name: Ann & Robert H Lurie Children's Hospital of Chicago class: OTHER briefSummary: This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for treating NAFLD in adolescents with obesity. conditions: Non-Alcoholic Fatty Liver Disease studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: 1:1 randomization primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: double blind placebo control whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: Empagliflozin 10 MG name: Placebo Oral Tablet measure: Hepatic Fat measure: Body mass index sex: ALL minimumAge: 16 Years maximumAge: 20 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06355297 id: 124CER19. briefTitle: Educational Intervention Related to Pelvic Floor Care in Females in Sport: ACTITUD acronym: ACTITUD overallStatus: ACTIVE_NOT_RECRUITING date: 2024-04-09 date: 2024-05-22 date: 2024-06-20 date: 2024-04-09 date: 2024-04-23 name: University of the Balearic Islands class: OTHER briefSummary: Pelvic floor dysfunctions (PFD) are especially prevalent among females who practice and compete in sport. One of the main reason is the great physical effort required to achieve the maximal sports performance. As conservational management, increasing the females' information is an important research line. However, gender stereotypes, embarrassment and normalization among females make it difficult to seek professional care. In this situation, prevention or management of PFD is limited.
To this end, all female who practice and compete in any sport in Spain will be invited to attend an educational online intervention with theoretical-practical content about PFD. As eligibility criteria, participants should train and compete in any sport, and have federative license from regional or national sports federation at the moment of the start of the study. Participants should have at least 16 years old. The investigators expect 400 athletes to fulfill the questionnaires, of which the investigators expect 200 to attend the educational intervention. Before the educational intervention, all females will reply an anonymous questionnaire to inform about their knowledge of PFD, daily practices related to PFD, influencing gender stereotypes and PFD self-reported diagnosis. One month later, this questionnaire will be sent to females (both athletes who attended the educational intervention or not) to describe changes after attending the online educational intervention and compared to those females who did not attend it. The main outcomes will be the level of knowledge about PF, the number of habits potentially related to PFD, and score of gender stereotyped beliefs. As an additional outcome, it will be considered the PFD self-reported symptomatology. conditions: Pelvic Floor Disorders studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A quasiexperimental controlled trial is designed, with two arms: an experimental group and a control group. primaryPurpose: PREVENTION masking: NONE count: 400 type: ESTIMATED name: Education about pelvic floor measure: Knowledge about pelvic floor measure: Habits related to pelvic floor dysfunctions measure: Gender stereotypes beliefs measure: Occurrence of symptoms related to pelvic floor dysfunctions sex: FEMALE minimumAge: 16 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: University of the Balearic Islands city: Palma De Mallorca state: Balearic Islands zip: 07122 country: Spain lat: 39.56939 lon: 2.65024 hasResults: False
nctId: NCT06355284 id: D5150-P briefTitle: Overcontrol and Suicide in PTSD acronym: OSP overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2026-02-27 date: 2026-04-30 date: 2024-04-09 date: 2024-04-09 name: VA Office of Research and Development class: FED briefSummary: High standards and self-discipline are prized in military culture, but drawbacks of overcontrol are often ignored. Overcontrol is characterized by over-regulated behavior and cognitive rigidity, driven by an intense need for perfection and control. It is frequently observed in people with obsessive-compulsive (OC) spectrum disorders, especially OC Personality Disorder (OCPD). Their inclination to set high expectations for others can strain social bonds. When grappling with mental health challenges, overcontrolled individuals often do so with limited social support, and as a result, tend to be at greater risk of developing more severe mental health symptoms, or suicidal thoughts and behaviors, over time.
3. A three-week online protocol for remote monitoring of social and emotional functioning. conditions: Compulsive Personality Disorder conditions: Stress Disorders, Post-Traumatic studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: OTHER count: 74 type: ESTIMATED name: Functional MRI measure: Number of potential participants screened per month meeting the overcontrol criterion. measure: Percentage of sessions completed by participants receiving MRI. measure: Percentage of remote questionnaires completed. sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Providence VA Medical Center, Providence, RI city: Providence state: Rhode Island zip: 02908-4734 country: United States name: Jennifer L Barredo role: CONTACT phone: 401-273-7100 phoneExt: 6290 email: Jennifer.Barredo@va.gov name: Jennifer L Barredo role: PRINCIPAL_INVESTIGATOR lat: 41.82399 lon: -71.41283 hasResults: False
nctId: NCT06355271 id: 2024-00019 briefTitle: Quality of Postoperative Analgesia and Functional Recovery After Elective Cesarean Delivery acronym: MoFe overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-08-31 date: 2025-09-01 date: 2024-04-09 date: 2024-04-10 name: Ente Ospedaliero Cantonale, Bellinzona class: OTHER briefSummary: Based on randomization, patients will receive a mixture for spinal anesthesia and will be followed in the following hours for the various outcomes and for functional recovery conditions: Obstetric Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Single center, multiple-blind, prospective, randomized, controlled trial in 3 parallel groups primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: Allocation will take place immediately before the intervention by the means of access to centralized, real-time allocation through a computer program. The identification code will be present on the data collection form (where the patient's name, surname or date of birth will not appear to ensure blinding of the study).
Personnel not directly involved with patient care, present during the randomization process, will sterilely prepare anesthesia solution while maintaining a total volume of 3,1 ml. This will allow blinding of patients, care providers and data collectors. The procedure will take place as a common clinical practice in our center. When performing spinal anesthesia, sterility is of fundamental importance, so it will not be possible to have the syringe used tagged. In the kit all materials will be sterile whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 63 type: ESTIMATED name: Fentanyl 1 name: Fentanyl2 name: Fentanyl 3 measure: Patient Controlled Analgesia morphine consumption measure: obstetric quality of recovery score measure: Visual Analogue Scale measure: pruritus measure: nausea and vomiting; considering it as a dichotomous variable (yes or no), without evaluating its entity measure: intraoperative hypotension measure: intraoperative opioids measure: satisfaction rate measure: intraoperative pain sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06355258 id: 20230817LX001 briefTitle: A Study of the Efficacy of Troxerutin in Preventing Thrombotic Events in COVID-19 Patients overallStatus: RECRUITING date: 2023-09-15 date: 2024-09 date: 2025-03 date: 2024-04-09 date: 2024-04-09 name: Westlake University class: OTHER name: Shaoxing Central Hospital briefSummary: The goal of this clinical trial is to learn if troxerutin works to prevent thrombotic events in mild or severe COVID-19 patients. It will also learn about the safety of troxerutin. The main questions it aims to answer are:
* Keep a diary of their symptoms and the number of times of thrombotic events, bleeding events and type II HIT-related thrombocytopenia conditions: COVID 19 Associated Coagulopathy studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: According to the inclusion criteria, participants will be randomly divided into mild patients and severe patients, and then patients with severe disease were randomly assigned to placebo + low molecular weight heparin group or troxerutin + low molecular weight heparin group, and patients with mild disease were randomly assigned to placebo group or troxerutin group primaryPurpose: PREVENTION masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 80 type: ESTIMATED name: Troxerutin name: Placebo name: placebo + low molecular weight heparin name: troxerutin + low molecular weight heparin measure: Overall number of thrombotic events through 28 days measure: Tolerability of anticoagulation therapy measure: Time to clinical improvement in patients through 28 days sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Shaoxing central hospital status: RECRUITING city: Shaoxing state: Zhejiang country: China name: Xu Li, Doctor role: CONTACT phone: 13811635032 email: lixu@westlake.edu.cn lat: 30.00237 lon: 120.57864 hasResults: False
nctId: NCT06355245 id: 2017/2160-31/1 briefTitle: MEDECA - Markers in Early Detection of Cancer acronym: MEDECA overallStatus: RECRUITING date: 2018-03-01 date: 2026-12 date: 2026-12 date: 2024-04-09 date: 2024-04-09 name: Danderyd Hospital class: OTHER briefSummary: Early diagnosis of cancer is key for improving patient outcomes, but cancers are difficult to diagnose if patients present with unspecific symptoms. The principal objective of the MEDECA (Markers in Early Detection of Cancer) study is to identify a multi-analyte blood test that can detect and map occult cancer within a mixed population of patients presenting with serious but unspecific symptoms. The study will include 1500 patients referred to the Diagnostic Center at Danderyd Hospital (DC DS), a multidisciplinary diagnostic center referral pathway for patients with radiological findings suggestive of metastasis without known primary tumor or suspicion of serious but unspecific symptoms. Blood samples are collected prior to a standardized and extensive cancer diagnostic work-up, including an expanded panel of biochemical analyses and extensive imaging such as computed tomography or magnetic resonance investigations. In collaboration with world-leading international scientists, the blood samples will be analyzed for a panel of novel and established blood biomarkers predictive of an underlying cancer, including markers of neutrophil extracellular traps, circulating tumor DNA, platelet mRNA profiling, affinity-based proteomics and nuclear magnetic resonance metabolomics. The diagnostic accuracy of the blood biomarkers with respect to cancer detection during the diagnostic work-up will be analyzed through machine learning. conditions: Cancer conditions: Diagnosis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 1500 type: ESTIMATED name: Blood sampling measure: Cancer diagnosis measure: Other diagnosis measure: Mortality measure: Cancer diagnosis sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Danderyd Hospital status: RECRUITING city: Stockholm country: Sweden name: Charlotte Thålin, M.D., Ph.D. role: CONTACT phone: +46709565120 email: charlotte.thalin@regionstockholm.se lat: 59.33258 lon: 18.0649 hasResults: False
nctId: NCT06355232 id: Vaxine-2301 briefTitle: Covid-19 and Influenza Oral Vaccine Study overallStatus: NOT_YET_RECRUITING date: 2024-04-21 date: 2024-04-21 date: 2025-04-21 date: 2024-04-09 date: 2024-04-09 name: Vaxine Pty Ltd class: INDUSTRY name: Australian Respiratory and Sleep Medicine Institute Ltd briefSummary: The purpose of the current study is to assess the effectiveness of protein-based COVID-19 or influenza vaccines when given individually or together via oral/ sublingual mucosal route instead of intramuscular delivery. The comparator will be a seasonal influenza vaccine which will also be administered with Advax-CpG adjuvant via the oral route. This study will use a cross-over design and everyone in the study will over a space of about 4 months receive both the COVID-19 and influenza vaccines. conditions: covid19 Infection conditions: Influenza, Human studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Randomised, controlled cross-over study primaryPurpose: PREVENTION masking: TRIPLE maskingDescription: A comparator vaccine (influenza) with an identical appearance will be used as the control. whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 100 type: ESTIMATED name: Covid-19 vaccine name: Influenza vaccine measure: SARS-CoV-2 Seroconversion measure: Influenza Seroconversion measure: SARS-CoV-2 Seroprotection measure: Influenza Seroprotection measure: SARS-CoV-2 Geometric mean titer fold change measure: Influenza geometric mean titer fold change measure: Safety assessment 1 measure: Safety assessment 2 measure: SARS-CoV-2 infection measure: Influenza infection measure: Antibody durability measure: Seroconversion in participants with and without evidence of past infection measure: Antibody GMT in participants with and without evidence of past infection measure: Antibody correlates of protection sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: ARASMI city: Adelaide state: South Australia zip: 5042 country: Australia lat: -34.92866 lon: 138.59863 hasResults: False
nctId: NCT06355219 id: IRB #19-066 briefTitle: Macrovascular and Microvascular Morbidity and Mortality After Metabolic Surgery Versus Medicines acronym: M6 overallStatus: ACTIVE_NOT_RECRUITING date: 2010-01-01 date: 2022-12-31 date: 2024-12-31 date: 2024-04-09 date: 2024-04-09 name: Ali Aminian class: OTHER briefSummary: The goal of this study is to compare the impact of metabolic surgery and a class of anti-diabetes medications (Glucagon-like peptide-1 receptor agonists,GLP-1 RAs) on occurrence of diseases involving small and large vessels such as heart disease, kidney disease, and disease of the retina (a part of the eye), as well as deaths. conditions: Type 2 Diabetes Mellitus conditions: Obesity conditions: Microvascular Disease conditions: Macrovascular Disease conditions: Major Adverse Cardiovascular Events conditions: Nephropathy conditions: Retinopathy conditions: Heart Failure conditions: All Cause Mortality studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 3932 type: ACTUAL measure: All-cause Mortality Rate measure: Incidence of MACE measure: Incidence of Nephropathy measure: Incidence of Retinopathy measure: Incidence of Components of MACE Separately measure: Change in weight percentage measure: Change HBA1c percentage measure: Trends of prescription and dispenses of medications for T2DM and cardio-vascular conditions measure: Progression of Chronic Kidney Disease (CKD) in Patients with CKD stages 3 and 4 at baseline measure: Cost-effectiveness of Metabolic Surgery vs GLP-1RAs measure: Incidence of Adverse Events After Metabolic Surgery sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06355206 id: NACRE20230306 briefTitle: Natural Course and Therapeutic Effect of Recurrent Acute Pancreatitis acronym: NACRE overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2034-12 date: 2034-12 date: 2024-04-09 date: 2024-04-09 name: Changhai Hospital class: OTHER briefSummary: The goal of this observational cohort study is to learn about the etiology, natural course, therapeutic effect and outcome of recurrent acute pancreatitis patients. The main question it aims to answer is:
Patients will be closely followed and clinical information will be recorded. conditions: Cohort Study conditions: Recurrent Acute Pancreatitis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 2000 type: ESTIMATED name: endoscopic intervention, surgery or conservative treatment measure: Recurrence rate of acute pancreatitis measure: Proportion of patients with different treatment measure: Characteristics of acute pancreatitis measure: Proportion of patients wtih pain in RAP patients measure: Proportion of patients with chronic pancreatitis measure: Evaluation of quality of life measure: Evaluation of psychological condition sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06355193 id: MZhou briefTitle: The Use of Isatidis Root and Forsythia Oral Liquid for the Treatment of Mild Cases of COVID-19: A Trial Clinical Study overallStatus: COMPLETED date: 2022-11-01 date: 2022-12-30 date: 2022-12-31 date: 2024-04-09 date: 2024-04-09 name: Central South University class: OTHER briefSummary: This study has significant implications for research, as it provides a basis for further studies on the antiviral effects of LGLQ Oral Liquid, encouraging more extensive clinical studies in larger populations and diverse age groups to validate these findings. For medical practice, the findings suggest that LGLQ can be considered an alternative treatment option for mild cases of COVID-19, especially in managing symptoms like fatigue, potentially broadening the range of effective treatments available to healthcare practitioners. In terms of policy, the demonstrated efficacy of LGLQ could lead to its inclusion in treatment guidelines for COVID-19 and other viral infections, fostering a more integrated approach combining Western medicine and Traditional Chinese Medicine in the global fight against pandemics. The insights from this study might prompt health policymakers to reassess the potential of herbal formulations in managing and treating infectious diseases and consider them in the development of future healthcare strategies and policies. conditions: Treatment of Mild Cases of COVID-19 studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 253 type: ACTUAL name: Langenlianqiao name: LianhuaQingWen name: placebo control group measure: Treatment and symptomatic improvement effects of LGLQ sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Changde Hospital city: Changde state: Hunan country: China lat: 29.04638 lon: 111.6783 hasResults: False